The report is part of FDA's Critical Path Initiative, established in 2004 to discern what challenges exist in moving a promising drug, biologic or device along the critical path from discovery, or proof of concept, to a marketable product

Date: 05/02/2007 , Publication: FDA News , Author: FDA

http://www.fda.gov/bbs/topics/NEWS/2007/NEW01626.html

Opinion: Are Price Controls the New Black?

...the legislation might just passand spell failure for the future of innovative drug development.

Date: 05/01/2007 , Publication: Pharmaceutical Executive , Author: Peter Pitts

http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=423214

Critical Mass for Critical Path?

...the rewards of collaboration now look greater than the risks....

Date: 05/01/2007 , Publication: Pharmaceutical Executive , Author: Dan Weiner, Mark Hovde

http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=423202

Washington Report: Pathways for Proteins

Innovators want exclusivity and clinical studies for follow-on biologics,

Date: 05/01/2007 , Publication: Pharmaceutical Executive , Author: Jill Wechsler

http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=423212

Ukraine Emerges as a Viable Location for Global Studies

Trials are on the rise in the country, where recruitment rates are high but custom procedures can pose a problem.

Date: 05/01/2007 , Publication: Applied Clinical Trials , Author: Olena Rudnyeva

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=4

< Previous Page 2 of 17 Next >

Search returned 161 items.